XML 90 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes
12 Months Ended
Mar. 31, 2012
Income Taxes [Abstract]  
Income Taxes

14.      Income Taxes

 

Income before income taxes consisted of (in thousands):

 

 

 

 

 

 

Year  Ended

        

March 31, 2012

March 26, 2011

March 27, 2010

         United States............................................................................................................. .

$     79,425

$     83,569

$    24,289

         Non-U.S......................................................................................................................

   558

   645

   2,394

 

$    79,983

$    84,214

   $   26,683

 

 

The provision (benefit) for income taxes consists of (in thousands):

 

 

 

 

 

Year  Ended

 

Current:

March 31, 2012

March 26, 2011

March 27, 2010

         Federal........................................................................................................................

 $       1,322

 $          163

$        (75)

         State............................................................................................................................

     518

     312

     8

         Non-U.S......................................................................................................................

     261

     204

     264

                    Total current tax provision...........................................................................

 $       2,101

 $          679

$        197

 

 

 

 

Deferred:

 

 

 

         U.S...............................................................................................................................         

$  (10,102)

$ (120,057)

$  (11,787)

         Non-U.S......................................................................................................................         

       1

       89

       (125)

                   Total deferred tax benefit.............................................................................

   (10,101)

   (119,968)

   (11,912)

                   Total tax benefit.............................................................................................

$    (8,000)

$ (119,289)

$  (11,715)

 

The provision (benefit) for income taxes differs from the amount computed by applying the statutory federal rate to pretax income as follows (in percentages):

 

 

 

 

 

 

Year  Ended

        

March 31, 2012

March 26, 2011

March 27, 2010

         Expected income tax provision at the U.S. federal statutory rate...................

        35.0

        35.0

        35.0

 

         Valuation allowance changes affecting the provision of income taxes........ .

(46.7)

(178.6)

(80.5)

 

        Foreign taxes at different rates................................................................................

0.1

(2.7)

 

        Foreign earnings taxed in the U.S............................................................................

0.2

 

        Refundable R&D credit............................................................................................

(0.3)

 

        Stock compensation..................................................................................................

1.0

(0.1)

4.2

 

         Nondeductible expenses..........................................................................................

0.1

1.1

0.4

 

         Other............................................................................................................................

       0.6 

       0.9 

        (0.2)

 

         Benefit for income taxes........................................................................................ .

       (10.0)

       (141.6)

       (43.9)

 

 

Significant components of our deferred tax assets and liabilities are (in thousands):

 

 

 

 

Year  Ended

        

March 31, 2012 

March 26, 2011 

         Deferred tax assets:

 

 

             Inventory valuation.............................................................................................................

$       3,240

$      4,494

             Accrued expenses and allowances....................................................................................

3,656

3,017

             Net operating loss carryforwards.......................................................................................

105,220

131,331

             Research and development tax credit carryforwards....................................................

36,032

37,464

             State tax credit carryforwards............................................................................................

244

250

Capitalized research and development............................................................................

9,779

14,773

Depreciation and Amortization.........................................................................................

159

             Other........................................................................................................................................

    18,747

    14,807

  Total deferred tax assets..............................................................................................

$   176,918

$  206,295

             Valuation allowance for deferred tax assets...................................................................

(29,075)

(68,380)

                    Net deferred tax assets..................................................................................................

$    147,843      

$    137,915      

 

 

 

         Deferred tax liabilities:

 

 

            Depreciation and amortization............................................................................................

$            287

$                 

             Acquisition intangibles.........................................................................................................

          5,348

           5,861

Total deferred tax liabilities..........................................................................................

$         5,635

   $      5,861

Total net deferred tax assets..........................................................................................

$    142,208 

   $  132,054

 

         These net deferred tax assets have been categorized on the Consolidated Balance Sheets as follows:

 

 

 

 

 

 

 

March 31, 2012 

March 26, 2011 

Current deferred tax assets...............................................................................................

$   53,137

$  30,797

Long-term deferred tax assets..........................................................................................

     89,071

  102,136

Long-term deferred tax liabilities.....................................................................................

           

      (879)

Total net deferred tax assets.............................................................................................

$  142,208

$132,054

 

         The current and long-term deferred tax assets are disclosed separately under their respective captions on the consolidated balance sheets, while the long term deferred tax liabilities are aggregated under the caption “Other long- term liabilities”  on the consolidated balance sheets.

 

         The valuation allowance decreased by $39.3 million in fiscal year 2012 and $157.8 million in fiscal year 2011.  In 2012 and 2011, the Company evaluated the ability to realize its deferred tax assets by using a three year forecast to determine the amount of net operating losses and other deferred tax assets that would be utilized if we achieved the results set forth in our three-year forecast.  The forecasted income was more than sufficient to absorb the remaining Federal net operating losses, research credits and most other Federal deductions; therefore, the valuation allowance that had remained on these deferred tax assets was released except for research credits that expire within the next year.  A valuation allowance was maintained on the Company’s capital loss carryforward because it will likely expire without being utilized.  A valuation allowance was also maintained on various state net operating losses and credits due to the likelihood that they will expire or go unutilized because the Company no longer has a significant apportionment in the jurisdiction in which the attribute was created. 

 

         At March 31, 2012, we had federal net operating loss carryforwards of $353.8 million.  Of that amount, $36.6 million related to companies we acquired during fiscal year 2002 and are, therefore, subject to certain limitations under Section 382 of the Internal Revenue Code.  Because the Company has elected the “with and without” method for purposes of tracking its excess stock deductions, the amount of Federal net operating loss included in deferred tax assets is $276 million, which yields a tax effected deferred tax asset of $96.6 million.  The Company had $77.8 million of excess stock deductions which are not included in deferred tax assets.  The tax benefit from these deductions will increase additional paid-in capital when they are deemed realized under the “with and without” method.  We had net operating losses in various states that total $104.8 million. The federal net operating loss carryforwards expire in fiscal years 2019 through 2029.  The state net operating loss carryforwards expire in fiscal years 2013 through 2029.  We also have non-U.S. net operating losses of $2.1 million, which do not expire. 

 

         There are federal research and development credit carryforwards of $21.4 million that expire in fiscal years 2013 through 2032.  There are $14.6 million of state research and development credits.  Of that amount, $2.9 million will expire in fiscal years 2022 through 2027.  The remaining $11.7 million of state research and development credits are not subject to expiration. 

 

         We have approximately $185 thousand of cumulative undistributed earnings in certain non-U.S. subsidiaries.  We have not recognized a deferred tax liability on these undistributed earnings because the Company currently intends to reinvest these earnings in operations outside the U.S.  The unrecognized deferred tax liability on these earnings is approximately $66 thousand. 

 

We record unrecognized tax benefits for the estimated risk associated with tax positions taken on tax returns.  A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows (in thousands):

 

Balance at March 26, 2011...................................................................................................................................

  $         0

Additions based on tax positions related to the current year..........................................................................

            

Reductions for tax positions of prior years.........................................................................................................

            

Settlements...............................................................................................................................................................

            

Reductions related to expirations of statutes of limitation..............................................................................

            

Balance at March 31, 2012...................................................................................................................................

  $          0

 

The Company does not believe that its unrecognized tax benefits will significantly increase or decrease during the next 12 months.

 

         We accrue interest and penalties related to unrecognized tax benefits as a component of the provision for income taxes.  We did not record any interest or penalties during fiscal year 2012.

 

         The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state and foreign jurisdictions. Fiscal years 2009 through 2012 remain open to examination by the major taxing jurisdictions to which we are subject.